Source: Oculus Innovative Sciences, Inc.
Oculus Innovative Sciences, Inc.
(NASDAQ: OCLS, warrants OCLSW), a specialty pharmaceutical company that
develops and markets solutions for the treatment of dermatological
conditions and advanced tissue care, today announced it has received a
new 510(k) clearance from the U.S. Food and Drug Administration (FDA)
for the company’s new post-dermal-procedures product.
Under the
supervision of a healthcare professional, the product is intended for
the removal of foreign material including microogranisms and debris from
postdermal procedures.
“Within my practice I utilize the
Microcyn Technology (hypochlorous acid or HOCl) post-procedure and have
been most impressed with its ability to accelerate the healing process,
manage post-procedure symptoms and protect against secondary infections.
I find these HOCl products to be safer, non-cytotoxic and a more
effective alternative to povidone-iodine and chlorhexidine. Now, with
this approval from the FDA, I believe my peers will benefit from adding
Microcyn-based products to their treatment protocols,” said Dr. Michael
Gold, board-certified dermatologist and cosmetic surgeon, and founder of
Gold Skin Care Center, Advanced Aesthetics Medical Spa, the Laser &
Rejuvenation Center and Tennessee Clinical Research Center, all located
in Nashville, Tennessee.
Oculus’ dermatology division,
IntraDerm, will begin marketing the postdermal-procedures product in
the United States beginning in March 2017.
About IntraDerm Pharmaceuticals
A
division of Oculus Innovative Sciences, IntraDerm Pharmaceuticals is a
global dermatology enterprise with an initial focus on Microcyn®
Technology and LipoGrid® Technologies. The division’s headquarters are
in Petaluma, California with the international sales operations in the
Netherlands, and manufacturing operations in the United States and Latin
America. More information can be found at www.intraderm.com.
About Oculus Innovative Sciences, Inc.
Oculus
Innovative Sciences is a specialty pharmaceutical company that develops
and markets unique and effective solutions for the treatment of
dermatological conditions and advanced tissue care. The company’s
products, which are sold throughout the United States and
internationally, have improved outcomes for more than five million
patients globally by reducing infections, itch, pain, scarring and
harmful inflammatory responses. The company's headquarters are in
Petaluma, California, with manufacturing operations in the United States
and Latin America. European marketing and sales are headquartered in
Roermond, Netherlands. More information can be found at www.oculusis.com.
No comments:
Post a Comment